INHIBITOR THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 19th, 2022 • Inhibitor Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Employment Agreement (the “Agreement”), entered into as of December 13, 2022 (the “Effective Date”), is made by and between Inhibitor Therapeutics, Inc., a Delaware corporation (the “Company”) and Francis E. O’Donnell (“Executive” and, together with the Company, the “Parties”).
INHIBITOR THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 19th, 2022 • Inhibitor Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Employment Agreement (the “Agreement”), entered into as of December 13, 2022 (the “Effective Date”), is made by and between Inhibitor Therapeutics, Inc., a Delaware corporation (the “Company”) and James A. McNulty (“Executive” and, together with the Company, the “Parties”).
Name Mayne Pharma Ventures Pty Ltd, an Australian company ACN 168 896 357 Short form name Mayne Pharma Notice details 1538 Main North Road, Salisbury South, SA 5106 Australia Facsimile: +61 3 9614 7022 Attention: General Counsel Name Inhibitor...Licence Agreement • December 19th, 2022 • Inhibitor Therapeutics, Inc. • Pharmaceutical preparations • Delaware
B Mayne Pharma and INTI are parties to a certain Stipulation and Agreement of Compromise, Settlement and Release dated as of September 9, 2022 pending approval by the Court of Chancery of the State of Delaware (the Stipulation), pursuant to which the 2018 Agreement is to be voided as of the Effective Date (defined) except as provided in the Stipulation, including with respect to the licence to Mayne Pharma of rights arising under certain INTI Patents (defined) and INTI’s right to a 9% cash royalty on future net sales, if any, of the Product (defined) in the United States and Mayne Pharma’s right to set off any royalties due to INTI on future net sales of the Product against USD 3,000,000.00 advance paid to INTI under the 2018 Agreement.
